Back to Search
BART BARLOGIE, MD
MD
Medical Oncology Physician
NPI: 1447340922Individual
Specialties, Licenses & Credentials
Hematology & Oncology Physician
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
R-3970(AR)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
287052(NY)
Research & Publications (20)
Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.
PMID 19636021·J Clin Oncol·2009
8-other
The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth.
PMID 19597185·Blood·2009
7-preclinical
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).
PMID 19554029·Leukemia·2009
6-review
Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204).
PMID 19546405·J Clin Oncol·2009
3-trial
Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.
PMID 19535776·J Natl Cancer Inst·2009
8-other
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.
PMID 19515721·Blood·2009
3-trial
RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma.
PMID 19458357·Blood·2009
7-preclinical
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.
PMID 19443657·Blood·2009
3-trial
Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.
PMID 19389881·Blood·2009
8-other
Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease.
PMID 19388929·Br J Haematol·2009
7-preclinical
Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile.
PMID 19344415·Br J Haematol·2009
8-other
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.
PMID 19228610·Blood·2009
8-other
An unusual clinical course of cardiac Ig deposition disease.
PMID 19219080·Bone Marrow Transplant·2009
5-case
International prognostic scoring system for Waldenstrom macroglobulinemia.
PMID 19196866·Blood·2009
4-observational
Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling.
PMID 19196662·Blood·2009
7-preclinical
High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis.
PMID 19191868·Eur J Haematol·2009
8-other
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma.
PMID 19171872·Blood·2009
8-other
Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols.
PMID 19120351·Br J Haematol·2009
8-other
Genetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma.
PMID 19657367·Leukemia·2009
8-other
The molecular characterization and clinical management of multiple myeloma in the post-genome era.
PMID 19657360·Leukemia·2009
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 10 E 102ND ST
NEW YORK, NY 10029 - Phone
- (212) 241-6756
Quick Facts
- NPI
- 1447340922
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile